Press coverage about Depomed (NASDAQ:DEPO) has trended somewhat positive on Monday, according to Accern. The research group scores the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Depomed earned a media sentiment score of 0.02 on Accern’s scale. Accern also gave news articles about the specialty pharmaceutical company an impact score of 45.3551988833214 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

A number of research analysts recently commented on the stock. Royal Bank of Canada set a $9.00 target price on shares of Depomed and gave the company a “hold” rating in a research report on Thursday, December 7th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $9.00 target price on shares of Depomed in a research report on Thursday, December 7th. BidaskClub raised shares of Depomed from a “sell” rating to a “hold” rating in a research report on Wednesday, December 6th. ValuEngine raised shares of Depomed from a “strong sell” rating to a “sell” rating in a research report on Tuesday, December 5th. Finally, Mizuho raised shares of Depomed from a “neutral” rating to a “buy” rating and set a $9.00 target price on the stock in a research report on Tuesday, December 5th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $11.64.

Shares of Depomed (NASDAQ:DEPO) traded down $0.02 during trading hours on Monday, reaching $7.77. 820,300 shares of the company were exchanged, compared to its average volume of 956,446. The firm has a market cap of $506.63, a PE ratio of -4.25 and a beta of 1.29. The company has a debt-to-equity ratio of 2.90, a quick ratio of 0.79 and a current ratio of 0.83. Depomed has a 12-month low of $4.31 and a 12-month high of $18.64.

Depomed (NASDAQ:DEPO) last issued its quarterly earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported $0.14 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.12 by $0.02. The firm had revenue of $95.40 million during the quarter, compared to analysts’ expectations of $99.11 million. Depomed had a negative net margin of 27.73% and a negative return on equity of 51.07%. Depomed’s quarterly revenue was down 13.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.28 EPS. analysts anticipate that Depomed will post -1.34 earnings per share for the current fiscal year.

In other Depomed news, insider Arthur J. Higgins purchased 75,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 14th. The stock was purchased at an average price of $8.16 per share, for a total transaction of $612,000.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 2.59% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “Depomed (DEPO) Receives Daily Media Impact Rating of 0.02” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at

Depomed Company Profile

Depomed, Inc is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).

Insider Buying and Selling by Quarter for Depomed (NASDAQ:DEPO)

Receive News & Ratings for Depomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed and related companies with's FREE daily email newsletter.